StageZero Life Sciences Ltd T.SZLS

Why an analyst forecast of $5.13 CAD?

[SAGDollar]

$5.13 CAD= $4.00 USD which is the minimum listing price for NASDAQ. Coincidence? I think not, the converted share price is literally within a penny of $4.00 USD. I think this is Noel's subtle hint.

[brad129]

this hasn't changed since Aug 9 so four months ago. It was always the $4 US or $.50 pre consolidation.  here is the link to confirm https://www.google.ca/amp/s/www.cantechletter.com/2020/08/stagezero-life-sciences-has-a-massive-upside-clarus-securities-says/amp/  

[SAGDollar]

Ahh yup. Thanks Brad, I think it's bed time lol. Cheers.

[ThisIsYerChance]

Yeah this is yer chance to go to bed BRAD.

[MissUniverse]

estimate 5.13   vs. reality 0.64 future looks bright ! our revenues are growing ! we are hiring people ! investors are happy !! the world is a beautiful place !!! OMG BOLTA

[davewho]

not sure if thats the case. It was always in C$ according to my TD account. It shows the new target of $5.13C and a reiterated buy by the Analyst Atkinson from Clarus dated 08Dec. After the latest CC. It does convert to slightly over the $4 mark needed for Nas listing.

[brad129]

I remember the price being all over the map just look back at the posts in August you will see. a quick google search gives you the info this was the top quote that came up for me.   For the current 2020 financial year, Clarus expects revenues of around 7.2 million US dollars in 2020 (almost exclusively from Covid-19 tests). ... With Covid testing volume and revenue

[skier59]

Well the good news is that once the Biden Admin takes control of the Office they said they will make TESTING throughout the USA as a TOP Priority. This will equate into increased testing at our Lab in Q1. Q4 numbers should be really good, far better than Q3 as mentioned in the CC, and Q1-2021 should be really big testing numbers along with Aristotle Launch. 

[Nailbiter1]

This post has been removed in accordance with Community Policy

[brad129]

Noel Atkinson Clarus Wall Street Analyst Ranked #252 out of 7,139 Analysts on TipRanks(#313 out of 14,919 overall experts) Noel Atkinson's Performance Success Rate 51% 109 out of 215 ratings were successful

[davewho]

Thanks Brad, Szls reports Q numbers in US$ but the 12 mon target price has always been C$ as far as I understood and TD showed it as C$. The latest change to the target I would guess is from the estimate for covid testing rev given during the CC. $19-$31mUS in 9-12 mons. Although you can call and ask him. Since SZLS main exchange is the TSX I would assume we are talking C$ targets. Yes you are

[MissUniverse]

i dont really understand now. cc was great. in Q3 we miss the estimated with a lot. but still de only 1 analyst increase sp to 5.13 ? based on missed results you increase the estimate? mathematically makes no sense.

[brad129]

according to Noel,  " other platforms are not accurately capturing the data and may be incorrectly multiplying certain data by the US$/C$ exchange rate."  

[davewho]

Thanks Brad for reaching out to Noel for info on the 12 mon target price. So is he saying his target was in C$ or US$? From your post I'm guessing he's saying its both depending which brokerage / site one uses? TD today shows $5.11 from yesterday's $5.13 so it appears to be floating slightly with the exchange rate. 

[capebretongirl]

That would be an approximate18% per month increase over the next 12 months - I for one would love to see such a consistent monthly rise as compared to waiting until say September 2021 for a 700% increase in order to make the $5.11 a reality. Ultimately, Clarus' prediction is based on the acceptance of Aristotle as a medical detection biopsy breakthrough - if it is endorsed on a widespread

[brad129]

I think you answered your own question if TD was $5.13 now 5.11 the target is in US figures. Clarus supplies their data to pension fund, mutual funds, and Hedge funds. believe it or not most things are in US dollars, I have suppliers with product made in Quebec and have to pay price in US dollars and converted on the daily spot price.